Weiner Adam B, Nguyen Anissa V, Kishan Amar U, Reiter Robert E, Litwin Mark S
Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA; Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA.
Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Eur Urol Oncol. 2024 Dec;7(6):1469-1477. doi: 10.1016/j.euo.2024.05.015. Epub 2024 Jun 8.
Adherence to guideline recommendations can improve the quality of care for patients with prostate cancer (PCa). Our aim was to assess adherence to guidelines for locoregional PCa by international region.
The study cohort comprised patients diagnosed with locoregional PCa in the 10-country Movember TrueNTH Global Registry (n = 62 688; 2013-2022). We assessed adherence to four quality metrics: (1) active surveillance for low-risk PCa; (2) definitive treatment within 12 mo of diagnosis for unfavorable-risk PCa; (3) no staging imaging for favorable-risk PCa; and (4) staging imaging for unfavorable-risk PCa. For χ analyses, we combined the three most recent years of data entered by region for each outcome, with adjustment for multiple tests (p = 0.05 ÷ 4 = 0.0125). We also conducted multivariable logistic regression and temporal analyses.
Active surveillance rates for low-risk PCa ranged from 85% in Australia/New Zealand (vs USA: adjusted odds ratio [aOR] 1.042, 95% confidence interval [CI] 0.740-1.520) to 14% in Central Europe (aOR 0.028, 95% CI 0.022-0.036). For patients with unfavorable-risk disease, the highest uptake rate for treatment within 12 mo of diagnosis was in Central Europe (98%; aOR 2.885, 95% CI 1.260-6.603), compared to 70% in Italy (aOR 0.031, 95%CI 0.014-0.072). The proportion of patients with favorable-risk disease who did not undergo imaging ranged from 94% in the USA to 30% in Italy (aOR 0.004, 95% CI 0.002-0.008), while the rate of imaging for unfavorable-risk PCa ranged from 8% in Hong Kong (aOR 65.222, 95% CI 43.676-97.398) to 39% in the USA (all χp < 0.0125). Regional temporal trends also varied.
In this international study comparing adherence to quality care metrics for the quality of care for locoregional PCa, we identified regional variance, possibly because of regional differences in cultural attitudes and health care structures. These benchmarks highlight opportunities for interventions to improve adherence to evidence-based guidelines.
Our study shows that adherence to recommended management goals for patients with prostate cancer varies greatly by global region.
遵循指南建议可提高前列腺癌(PCa)患者的护理质量。我们的目的是评估国际各地区对局限性PCa指南的遵循情况。
研究队列包括在10个国家的“莫氏胡须月真实健康全球注册研究”中被诊断为局限性PCa的患者(n = 62688;2013 - 2022年)。我们评估了对四项质量指标的遵循情况:(1)对低风险PCa进行主动监测;(2)对高危PCa在诊断后12个月内进行确定性治疗;(3)对低危PCa不进行分期影像学检查;(4)对高危PCa进行分期影像学检查。对于χ分析,我们将各地区输入的最近三年关于每个结果的数据进行合并,并对多重检验进行校正(p = 0.05÷4 = 0.0125)。我们还进行了多变量逻辑回归和时间分析。
低风险PCa的主动监测率从澳大利亚/新西兰的85%(与美国相比:调整后的优势比[aOR]为1.042,95%置信区间[CI]为0.740 - 1.520)到中欧的14%(aOR为0.028,95%CI为0.022 - 0.036)。对于高危疾病患者,诊断后12个月内治疗的最高接受率在中欧(98%;aOR为2.885,95%CI为1.260 - 6.603),而意大利为70%(aOR为0.031,95%CI为0.014 - 0.072)。低危疾病患者未进行影像学检查的比例从美国的94%到意大利的30%(aOR为0.004,95%CI为0.002 - 0.008),而高危PCa的影像学检查率从香港的8%(aOR为65.222,95%CI为43.676 - 97.398)到美国的39%(所有χp < 0.0125)。各地区的时间趋势也有所不同。
在这项比较局限性PCa护理质量对质量护理指标遵循情况的国际研究中,我们发现了地区差异,这可能是由于文化态度和医疗保健结构的地区差异所致。这些基准突出了进行干预以提高对循证指南遵循情况的机会。
我们的研究表明,全球各地区对前列腺癌患者推荐管理目标的遵循情况差异很大。